Cargando…

The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution

The Omicron BA.1 variant of SARS-CoV-2 escapes convalescent sera and monoclonal antibodies that are effective against earlier strains of the virus. This immune evasion is largely a consequence of mutations in the BA.1 receptor binding domain (RBD), the major antigenic target of SARS-CoV-2. Previous...

Descripción completa

Detalles Bibliográficos
Autores principales: Moulana, Alief, Dupic, Thomas, Phillips, Angela M, Chang, Jeffrey, Roffler, Anne A, Greaney, Allison J, Starr, Tyler N, Bloom, Jesse D, Desai, Michael M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949795/
https://www.ncbi.nlm.nih.gov/pubmed/36803543
http://dx.doi.org/10.7554/eLife.83442
_version_ 1784893023798165504
author Moulana, Alief
Dupic, Thomas
Phillips, Angela M
Chang, Jeffrey
Roffler, Anne A
Greaney, Allison J
Starr, Tyler N
Bloom, Jesse D
Desai, Michael M
author_facet Moulana, Alief
Dupic, Thomas
Phillips, Angela M
Chang, Jeffrey
Roffler, Anne A
Greaney, Allison J
Starr, Tyler N
Bloom, Jesse D
Desai, Michael M
author_sort Moulana, Alief
collection PubMed
description The Omicron BA.1 variant of SARS-CoV-2 escapes convalescent sera and monoclonal antibodies that are effective against earlier strains of the virus. This immune evasion is largely a consequence of mutations in the BA.1 receptor binding domain (RBD), the major antigenic target of SARS-CoV-2. Previous studies have identified several key RBD mutations leading to escape from most antibodies. However, little is known about how these escape mutations interact with each other and with other mutations in the RBD. Here, we systematically map these interactions by measuring the binding affinity of all possible combinations of these 15 RBD mutations (2(15)=32,768 genotypes) to 4 monoclonal antibodies (LY-CoV016, LY-CoV555, REGN10987, and S309) with distinct epitopes. We find that BA.1 can lose affinity to diverse antibodies by acquiring a few large-effect mutations and can reduce affinity to others through several small-effect mutations. However, our results also reveal alternative pathways to antibody escape that does not include every large-effect mutation. Moreover, epistatic interactions are shown to constrain affinity decline in S309 but only modestly shape the affinity landscapes of other antibodies. Together with previous work on the ACE2 affinity landscape, our results suggest that the escape of each antibody is mediated by distinct groups of mutations, whose deleterious effects on ACE2 affinity are compensated by another distinct group of mutations (most notably Q498R and N501Y).
format Online
Article
Text
id pubmed-9949795
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-99497952023-02-24 The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution Moulana, Alief Dupic, Thomas Phillips, Angela M Chang, Jeffrey Roffler, Anne A Greaney, Allison J Starr, Tyler N Bloom, Jesse D Desai, Michael M eLife Evolutionary Biology The Omicron BA.1 variant of SARS-CoV-2 escapes convalescent sera and monoclonal antibodies that are effective against earlier strains of the virus. This immune evasion is largely a consequence of mutations in the BA.1 receptor binding domain (RBD), the major antigenic target of SARS-CoV-2. Previous studies have identified several key RBD mutations leading to escape from most antibodies. However, little is known about how these escape mutations interact with each other and with other mutations in the RBD. Here, we systematically map these interactions by measuring the binding affinity of all possible combinations of these 15 RBD mutations (2(15)=32,768 genotypes) to 4 monoclonal antibodies (LY-CoV016, LY-CoV555, REGN10987, and S309) with distinct epitopes. We find that BA.1 can lose affinity to diverse antibodies by acquiring a few large-effect mutations and can reduce affinity to others through several small-effect mutations. However, our results also reveal alternative pathways to antibody escape that does not include every large-effect mutation. Moreover, epistatic interactions are shown to constrain affinity decline in S309 but only modestly shape the affinity landscapes of other antibodies. Together with previous work on the ACE2 affinity landscape, our results suggest that the escape of each antibody is mediated by distinct groups of mutations, whose deleterious effects on ACE2 affinity are compensated by another distinct group of mutations (most notably Q498R and N501Y). eLife Sciences Publications, Ltd 2023-02-21 /pmc/articles/PMC9949795/ /pubmed/36803543 http://dx.doi.org/10.7554/eLife.83442 Text en © 2023, Moulana, Dupic et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Evolutionary Biology
Moulana, Alief
Dupic, Thomas
Phillips, Angela M
Chang, Jeffrey
Roffler, Anne A
Greaney, Allison J
Starr, Tyler N
Bloom, Jesse D
Desai, Michael M
The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution
title The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution
title_full The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution
title_fullStr The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution
title_full_unstemmed The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution
title_short The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution
title_sort landscape of antibody binding affinity in sars-cov-2 omicron ba.1 evolution
topic Evolutionary Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949795/
https://www.ncbi.nlm.nih.gov/pubmed/36803543
http://dx.doi.org/10.7554/eLife.83442
work_keys_str_mv AT moulanaalief thelandscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT dupicthomas thelandscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT phillipsangelam thelandscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT changjeffrey thelandscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT rofflerannea thelandscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT greaneyallisonj thelandscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT starrtylern thelandscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT bloomjessed thelandscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT desaimichaelm thelandscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT moulanaalief landscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT dupicthomas landscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT phillipsangelam landscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT changjeffrey landscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT rofflerannea landscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT greaneyallisonj landscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT starrtylern landscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT bloomjessed landscapeofantibodybindingaffinityinsarscov2omicronba1evolution
AT desaimichaelm landscapeofantibodybindingaffinityinsarscov2omicronba1evolution